Rockefeller Capital Management L.P. Sells 304,266 Shares of BioLife Solutions, Inc. $BLFS

Rockefeller Capital Management L.P. cut its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 30.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 705,863 shares of the medical equipment provider’s stock after selling 304,266 shares during the quarter. Rockefeller Capital Management L.P. owned 1.46% of BioLife Solutions worth $17,068,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Global Retirement Partners LLC acquired a new stake in shares of BioLife Solutions during the 4th quarter worth approximately $30,000. Kemnay Advisory Services Inc. acquired a new position in shares of BioLife Solutions during the 4th quarter valued at $35,000. Quarry LP boosted its stake in BioLife Solutions by 50.9% during the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after acquiring an additional 713 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in BioLife Solutions by 42.4% during the fourth quarter. Hantz Financial Services Inc. now owns 2,673 shares of the medical equipment provider’s stock worth $65,000 after acquiring an additional 796 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in BioLife Solutions by 82.0% in the third quarter. PNC Financial Services Group Inc. now owns 4,425 shares of the medical equipment provider’s stock worth $113,000 after purchasing an additional 1,994 shares during the period. 93.24% of the stock is currently owned by institutional investors.

BioLife Solutions Stock Down 0.1%

Shares of BLFS opened at $24.88 on Wednesday. The business’s fifty day moving average is $23.63 and its 200 day moving average is $22.94. BioLife Solutions, Inc. has a 12-month low of $17.86 and a 12-month high of $29.62. The stock has a market cap of $1.22 billion, a P/E ratio of -310.96 and a beta of 2.00.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. The business had revenue of $27.50 million during the quarter, compared to analyst estimates of $25.66 million. On average, analysts expect that BioLife Solutions, Inc. will post 0.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on BLFS. Zacks Research downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 12th. Wall Street Zen upgraded BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research report on Monday, April 20th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, BioLife Solutions currently has a consensus rating of “Hold” and a consensus target price of $32.00.

Insider Activity at BioLife Solutions

In related news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $23.70, for a total value of $15,405,000.00. Following the sale, the insider owned 4,757,165 shares in the company, valued at $112,744,810.50. This represents a 12.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold 1,200,000 shares of company stock worth $28,125,000 over the last ninety days. Insiders own 2.20% of the company’s stock.

BioLife Solutions Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.